Search results for: Alzheimer's
Filter search results
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
…children). For example, it is common for spouses to provide care to people with Parkinson’s and Alzheimer’s disease and for parents to provide care to children with cystic fibrosis and…
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
…are equity, informal carer health-related quality of life (HRQoL) spillovers, productivity, and wider health sector benefits. Two case studies in Alzheimer’s disease and Spinal Muscular Atrophy show that different ways…
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
…New treatments for Alzheimer’s disease look likely to be the next test for the technology appraisal processes and anticipated breakthroughs in areas such as digital health technologies and diagnostics will…
When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
1 March 2022
…sclerosis Alzheimer’s disease Sickle cell disease Our earlier report on the measurement of QOL for HTA provides a summary of the potential alternatives to generic preference-based measures for measuring QOL. Click to…
Dementia: The R&D Landscape
1 November 2015
…observations include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are likely due to lower success…
Evaluating Medical Innovation: The Societal View
8 April 2010
…factors are reviewed in the Briefing and case studies are provided for Alzheimer’s disease and multiple sclerosis. The authors acknowledge that including a broader range of factors in evaluations in…
CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation
14 September 2021
…estimate will be lost due to H.R. 3 may be the 5th treatment on the market for migraines while another may be a cure for Alzheimer’s. One society may be…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
…of the high social value of spill-overs from inherently risky pharmaceutical innovation. Spending on today’s cancer therapy supports R&D for tomorrow’s cure for Alzheimer’s disease. Also, it was the “re-tooling”…
Recently published: Are Wider Societal Effects Considered in Healthcare Decision-making?
29 February 2016
…by OHE’s Martina Garau, Koonal Shah, and Adrian Towse. There is evidence suggesting that, in certain diseases areas such as Alzheimer’s disease, depression, and breast cancer, health interventions can produce…